Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects

Bromocriptine-QR is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population by as yet incompletely delineated mechanisms. However, a chronic state of elevated sympa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cincotta, Anthony H., Cersosimo, Eugenio, Alatrach, Mariam, Ezrokhi, Michael, Agyin, Christina, Adams, John, Chilton, Robert, Triplitt, Curtis, Chamarthi, Bindu, Cominos, Nicholas, DeFronzo, Ralph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407769/
https://www.ncbi.nlm.nih.gov/pubmed/36012132
http://dx.doi.org/10.3390/ijms23168851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407769/
https://www.ncbi.nlm.nih.gov/pubmed/36012132
http://dx.doi.org/10.3390/ijms23168851

Ejemplares similares